Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized observer-blind study of an mRNA seasonal influenza vaccine in adults aged 65 years and older
2026-526682-14-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, single-blind trial of GSK4382276A and influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) antigen (propiolactone inactivated) in influenza (2 arms), sponsored by GSK. Primary endpoints: Efficacy against laboratory-confirmed influenza illness, Solicited local and systemic adverse events and 3 more. Planned start Oct 2026; status: authorised.
02
Drugs
GSK4382276Ainfluenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) antigen (propiolactone inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on 2026-526682-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526682-14-00.